Fresenius SE & Co. KGaA

Medicine & Research - 2011

10.11.2011	Fresenius Medical Care introduces 2008K@home™ hemodialysis delivery system in North America
	Text as PDF file
04.10.2011	Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium
	Text as PDF file
20.09.2011	Fresenius Biotech’s Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
	Text as PDF file
27.06.2011	Fresenius Medical Care announces increased effectiveness of online hemodiafiltration treatment: Studies confirm improved dialysis-patient survival
	Text as PDF file
22.06.2011	Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy
	Text as PDF file
07.06.2011	ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab® − benefit in overall survival of cancer patients demonstrated
	Text as PDF file
06.06.2011	Fresenius Biotech’s ATG-Fresenius S approved in Austria for GVHD prophylaxis in stem cell transplantations
	Text as PDF file
17.03.2011	Fresenius Medical Care’s Patient Safety Organization Gains Official Certification by U.S. Department of Health and Human Services
	Text as PDF file
08.03.2011	Fresenius Biotech’s ATG-Fresenius S approved for GVHD prophylaxis in stem cell transplantations in Germany
	Text as PDF file
27.01.2011	Fresenius Biotech announces agreement with Swedish Orphan Biovitrum for distribution of Removab®
	Text as PDF file

Home > Press > Press Releases > Medicine & Research > 2011